WEBINAR — Adversity Level Determination in Nonclinical Studies
Adversity Level Determination in Nonclinical Studies
This complimentary webinar offers expert insight into how data is interpreted on toxicology studies. More specifically, we provide you with an insider’s view on common practices and guidances followed by contract research organizations to characterize adversity.
Case studies included:
- Overt toxicity, exaggerated pharmacology, and changes in various markers of toxicity in the context of other safety endpoints
- How to approach data interpretation on toxicology studies to classify adverse vs. non-adverse effects
You may also be interested in the following:
- Preclinical Drug Development Solutions
- Podcast — Overcoming Drug Development Pathway Challenges with Dr. Ghatnekar
- Safety Pharmacology Capabilities
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.